The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform
Sarita Sonalkar - One of the best experts on this subject based on the ideXlab platform.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:Purpose of Review To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. Recent Findings The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. Summary The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:Purpose of Review To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. Recent Findings The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. Summary The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
Jade M. Shorter - One of the best experts on this subject based on the ideXlab platform.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:Purpose of Review To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. Recent Findings The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. Summary The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:Purpose of Review To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. Recent Findings The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. Summary The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
Courtney A. Schreiber - One of the best experts on this subject based on the ideXlab platform.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:Purpose of Review To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. Recent Findings The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. Summary The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
-
Recent Advances in the Medical Management of Early Pregnancy Loss
Current Obstetrics and Gynecology Reports, 2020Co-Authors: Jade M. Shorter, Courtney A. Schreiber, Sarita SonalkarAbstract:Purpose of Review To provide an update on advances in Medical Management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens. Recent Findings The utilization of misoprostol for Medical Management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use. Summary The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of Medical Management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
Mitchell D. Creinin - One of the best experts on this subject based on the ideXlab platform.
-
Medical Management of early pregnancy failure: efficacy.
Seminars in reproductive medicine, 2008Co-Authors: Beatrice A. Chen, Mitchell D. CreininAbstract:Early pregnancy failure is a common pregnancy complication. This article reviews the efficacy of Medical Management of early pregnancy failure. Nonsurgical treatments, including expectant and Medical Management, are reasonable alternatives to surgical Management depending on the clinical situation and the patient's requests. Possible regimens in Medical Management of early pregnancy failure include misoprostol alone or mifepristone in conjunction with misoprostol. However, many studies of Medical Management may underestimate success rates due to inconsistent inclusion criteria, different dosing regimens, and varying definitions of failed treatment. Clinicians need to understand the range of efficacy of these regimens to provide appropriate counseling to patients.
Beatrice A. Chen - One of the best experts on this subject based on the ideXlab platform.
-
Medical Management of early pregnancy failure: efficacy.
Seminars in reproductive medicine, 2008Co-Authors: Beatrice A. Chen, Mitchell D. CreininAbstract:Early pregnancy failure is a common pregnancy complication. This article reviews the efficacy of Medical Management of early pregnancy failure. Nonsurgical treatments, including expectant and Medical Management, are reasonable alternatives to surgical Management depending on the clinical situation and the patient's requests. Possible regimens in Medical Management of early pregnancy failure include misoprostol alone or mifepristone in conjunction with misoprostol. However, many studies of Medical Management may underestimate success rates due to inconsistent inclusion criteria, different dosing regimens, and varying definitions of failed treatment. Clinicians need to understand the range of efficacy of these regimens to provide appropriate counseling to patients.
